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Essentials  
Complement activation has a pathogenic role in thrombotic antiphospholipid syndrome 
(APS)  
Coagulation proteases such as factor Xa can activate complement proteins  
Complement activation markers were elevated in anticoagulated thrombotic APS patients  
Complement activation decreased in APS patients switching from warfarin to rivaroxaban 
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Abstract 
Background 
Complement activation may play a major role in the pathogenesis of thrombotic 
antiphospholipid syndrome (APS). Coagulation proteases such as factor Xa can activate 
complement proteins.  
Aims 
 To establish whether rivaroxaban, a direct factor Xa inhibitor, limits complement activation 
compared to warfarin in APS patients with previous venous thromboembolism (VTE). 
Methods 
111 APS patients with previous VTE, on warfarin target INR 2.5, had blood samples taken at 
baseline and at day 42 after randomisation in the RAPS (Rivaroxaban in Antiphospholipid 
Syndrome) trial. Fifty-six patients remained on warfarin and 55 switched to rivaroxaban. 
Fifty-five normal controls (NC) were also studied. Markers of complement activation (C3a, 
C5a, terminal complement complex (SC5b-9) and Bb fragment), were assessed.  
Results 
APS patients had significantly higher complement activation markers compared to NC at 
both time points irrespective of the anticoagulant. There were no differences between the 
two patient groups at baseline, or patients remaining on warfarin at day 42. In 55 patients 
randomised to rivaroxaban, C3a, C5a and SC5b-9 were significantly lower at day 42; median 
(ng/mL) [confidence interval] 64 [29-125] vs 83 [35-147], 9 [2–15] vs 12 [4 -18] and 171 [56-
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245] vs 201 [66-350] respectively, but levels of Bb were unchanged. There were no 
correlations between rivaroxaban levels and complement activation markers.  
 Conclusions  
APS patients with previous VTE on warfarin exhibit significantly increased complement 
activation, which is likely to occur via the classical pathway, and is decreased by rivaroxaban 
administration. Rivaroxaban may therefore potentially provide benefit additional to its 
anticoagulant effect in this patient group by limiting complement activation. 
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Introduction 
The complement system is an important part of the innate immune system, forming an 
important link with adaptive immune responses [1], and interacts directly with the 
haemostatic system [2;3]. It is activated via the classical, alternative and lectin pathways 
(CP, AP and LP respectively) [4], which converge at the level of C3. The CP is triggered by 
antigen-antibody complexes, and the LP by sugars recognised primarily by mannose binding 
lectin. Following activation of several proteases, a C3 convertase proteolyses C3 into C3a 
and C3b, the latter forming a C5 convertase. In the AP, C3 is hydrolysed spontaneously and 
then binds factor B (FB), which is cleaved by factor D to produce fragment Bb and a C3 
convertase, with the liberation of fragment C3a [5]. The AP can also be potentiated by 
plasma kallikrein, which cleaves FB. C3b acts as the central effector molecule in C5 
convertase, with cleavage of C5, producing C5a and C5b. The terminal complement complex 
(TCC, SC5b-9) is generated by the assembly of C5b through C9 and forms the membrane 
attack complex, mediating the irreversible target cell membrane damage associated with 
complement activation. The anaphylatoxin C3a has a half-life of several hours, but in serum 
is cleaved rapidly to the more stable C3a-desArg, which provides a marker of complement 
activation [6]. C5a and SC5b-9 levels are markers of terminal complement pathway 
activation [7-9]. FB is unique to the alternative complement pathway, hence Bb fragment is 
a marker of AP activation [10].  
Disorders of complement activation or dysregulation can result in excessive complement 
generation and thrombosis, such as in paroxysmal nocturnal haemoglobinuria (PNH) [11], 
atypical haemolytic uremic syndrome (aHUS) [12], thrombotic thrombocytopenic purpura 
(TTP) [13] and antiphospholipid syndrome (APS) [14;15].  
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Clinical studies and murine models suggest involvement of the complement system in 
thrombotic APS. APS patients exhibit low serum complement C3 and C4 levels, with C3a, 
C3a-desArg and C4a significantly higher than in healthy controls, suggesting that APS-
associated hypocomplementemia is due to complement activation rather than complement 
deficiency [14;16]. The potent inflammatory mediator C5a is implicated in APS, and 
complement inhibition may ameliorate thrombosis induced by antiphospholipid antibodies 
(aPL) [17;18]. Mice treated with IgG from APS patients with high levels of aPL, subjected to a 
femoral vein pinch model of thrombosis, developed larger thrombi and higher TF activity 
than controls [19]. The co-administration of rEV576 (coversin), a recombinant protein 
inhibitor of C5 activation, resulted in significantly smaller thrombi and reduced tissue factor 
(TF) activity [19]. Furthermore, complement activation is a central mechanism in murine 
aPL‐induced pregnancy loss and intrauterine fetal growth restriction [20;21]. Widespread 
complement activation may also play a role in catastrophic APS (CAPS) (22-24)and anecdotal 
case reports suggest possible efficacy of eculizumab (Soliris), a humanised monoclonal 
antibody that inhibits C5 [25;26].   
Limited in vitro data suggest that thrombin, as well as coagulation factors (F) XIa, Xa, IXa, 
and plasmin, can activate C5 to C5a in the absence of C3 [2]. Complement activation can 
amplify coagulation and inhibit fibrinolysis, through C5a, which induces expression of TF and 
plasminogen activator inhibitor 1 (PAI-1) [2]. The anti-complement activation effect of 
heparin, first described in 1929 by Ecker and Gross [27], may be through its inhibitory 
effects on thrombin and FXa, which are known to cause activation of C3 and C5 producing 
C3a, C5a and subsequently SC5b-9.  
We hypothesised that rivaroxaban, as a direct FXa inhibitor has the potential to inhibit FXa 
induced complement activation of C5 to C5a. The aim of this study was to establish, in 
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patients with APS and previous venous thromboembolism (VTE), whether rivaroxaban 
administration limits complement activation compared to warfarin, the current mainstay of 
anticoagulation in this patient group. 
 
Patients and methods 
Patients, normal controls and blood sampling  
Venous blood samples were collected, as part of translational research, from patients 
recruited to the RAPS (Rivaroxaban in Antiphospholipid Syndrome; 
[http://isrctn.org/ISRCTN68222801] prospective randomised controlled trial (RCT) of 
rivaroxaban versus warfarin in patients with thrombotic APS, with or without systemic lupus 
erythematosus (SLE) [28]. The patients comprised those with previous venous 
thromboembolism (VTE), on long-term anticoagulation with warfarin, target INR 2.5 (range 
2.0-3.0), who were eligible for RAPS and fulfilled the revised international consensus criteria 
for definite APS [29]. All patients were on warfarin for at least 3 months following a VTE 
prior to entry into the study and had no new thrombotic events during the trial treatment 
period. The current study was approved by the Research Ethics Committee and the 
Research and Development Office at University College London Hospitals (UCLH) NHS Trust 
(Reference number: 13/EM/0150). All patients gave informed, written consent for the 
translational research (Reference number: 12/SC/0566). Patients were randomised to 
remain on warfarin target INR 2.5 or to switch to rivaroxaban 20 mg once daily.  
Venous samples were taken into 4mL Vacutainer K2E tubes containing 7.2mg EDTA 
(Vacutainer K2E; Becton Dickinson, Oxford), or 0.105M citrate (Vacutainer 9NC), using a 21 
gauge butterfly needle with minimal stasis, at baseline (day 0, on warfarin) and day 42 
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(range 30-56 days after randomisation). In patients randomised to receive rivaroxaban, 
blood samples were taken at 2-4 hours following the last dose of rivaroxaban. Samples were 
also collected from 55 normal controls (NC), who were members of staff, previously shown 
to be aPL negative.  Individuals who were pregnant or receiving oestrogen-containing 
preparations were excluded from the study as there can be increased levels or activation of 
complement in these situations [30;31]. EDTA (complement activation markers) and citrate 
(all haemostasis tests) plasmas were prepared within 1 hour of collection by double 
centrifugation at 2000g for 15 minutes and stored at -80°C. Immediately prior to analysis, 
the samples were thawed at 37°C.  Of the total 116 patients (57 rivaroxaban and 59 
warfarin), including 22 patients with SLE, recruited to the RAPS trial and available for study, 
four patients were excluded due to plasma haemolysis and one because there was no day 
42 sample leaving 111 patients (55 on rivaroxaban and 56 on warfarin) with 11 SLE patients 
in each group.  
 
Laboratory assays 
Antiphospholipid antibodies 
All aPL assays were performed at baseline. Lupus anticoagulant (LA) was assessed by Dilute 
Russell’s viper venom time (DRVVT) using LA1/LA2 screen/confirm reagents (Siemens 
Healthcare) in equal volume mixtures with pooled normal plasma, to correct for 
warfarin-induced coagulation factor deficiencies, in accordance with international and 
national guidelines [32;33]; and the Taipan venom time/Ecarin clotting time ratio (TVT/ECT), 
Diagnostic Reagents Ltd, Thame, UK), which shows little impact of warfarin. 
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IgG and IgM anticardiolipin (aCL) and anti-β2 glycoprotein I (aβ2GPI) antibodies were 
assessed by ELISA (Quanta Lite, Inova, Werfen).  Moderate/high aCL positivity was defined 
as >20 GPLU/MPLU, and aβ2GPI positivity as >20 SGu/SMu.  
Complement assays 
Complement activation markers were measured as C3a-desArg (C3a), C5a-des-Arg (C5a), 
SC5b-9 and Bb fragment (Bb) using commercial enzyme-linked immunosorbent assay (ELISA) 
(MicroVue kits, Quidel Corp, from Pathway Diagnostics Ltd, Dorking, UK). Samples from each 
patient were tested on the same ELISA plate. The intra- and inter-assay coefficient of 
variation (CV) was as follows: C3a 1.8% and 3.4%; C5a 1.9% and 2.4%; SC5b-9 2.0% and 
2.6%; Bb 1.9% and 2.7%, respectively. 
International Normalised Ratio and rivaroxaban levels 
International Normalised Ratio (INR) values were measured using  PT Fib HS Plus on a 
TOP500 (Werfen, Warrington, UK), using an analyser specific ISI  in the two groups of 
patients on warfarin. Rivaroxaban levels were measured in 55 patients receiving rivaroxaban 
on day 42 using an amidolytic anti-Xa assay (Biophen DiXaI; Hyphen BioMed, Neuville-Sur-
Oise, France). 
 
Statistical analysis 
There were no suitable data on which to base power calculations; this was a pilot study 
based on the samples available from the RAPS trial. Data analysis was performed using 
MiniTab 16 (Minitab Ltd, Coventry, UK) and GraphPad Prism® version 6 (GraphPad Software, 
Inc. La Jolla, USA). Results were reported as median or mean based on the distribution of 
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results with 95% confidence interval (CI). Multiple group comparisons were performed using 
Kruskal-Wallis ANOVA and paired comparisons using Mann-Whitney ‘U’ test after adjusting 
the significant p-values by Bonferroni correction. Examination of correlations was 
performed using the Spearman rank correlation. Normal ranges of complement activation 
markers were derived as mean ±2SD, after log transformation of data where necessary. A p 
value of <0.05 was considered significant.   
 
Results 
INR and rivaroxaban levels 
INR at baseline: (median [CI]) 2.7 [2.5 to 3.0] and 2.6 [2.4-2.9] for the two groups and 2.8 
[2.4 to 2.9]  in those remaining on warfarin at day 42. In patients randomised to 
rivaroxaban, the rivaroxaban levels at day 42 varied between <50 and 461ng/mL: median 
[CI] 155 [139-184].  
Antiphospholipid antibodies  
Table 1 shows the baseline characteristics of the study subjects. 14/55 (25%) and 19/56 
(34%) patients were triple aPL positive (presence of LA, aCL and aβ2GPI antibodies) in the 
rivaroxaban treated group and warfarin treated group, respectively. LA was present in 43/55 
(78%) in the rivaroxaban treated group and 40/56 (71%) of the patients who remained on 
warfarin.    
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Complement activation markers 
The normal reference ranges, as measured in the 55 NC, for C3a, C5a, SC5b-9 and Bb 
fragment were: 27-96 ng/mL, 0.8-13.0 ng/mL, 60-164 ng/mL and 0.7-1.7 µg/mL, 
respectively. APS patients had significantly higher median complement activation markers 
compared with NC at both baseline and day 42, irrespective of the anticoagulant (p<0.0001 
for C3a, C5a, SC5b-9 and Bb fragment; Fig. 1-4). At baseline (when all patients were on 
warfarin), there were no differences between the two patient groups for these markers and 
there were no differences at day 42 in those who remained on warfarin. C3a, C5a, SC5b-9 
and Bb were elevated in 42 (38%), 44 (40%), 80 (72%) and 33 (30%) of the 111 patients, 
respectively.  
Increased C3a, C5a, SC5b-9 and Bb fragment levels were not associated with the presence of 
triple positivity for aPL, or with the presence of LA. Furthermore, no significant differences 
were observed in the complement activation markers between patients with primary APS 
and those with SLE-associated APS on warfarin or rivaroxaban. Increased complement 
activation markers were not associated with higher or lower INR values. The 55 patients 
randomised to receive rivaroxaban displayed significantly lower median C3a, C5a and SC5b-
9 on day 42 (levels on day 42, compared to baseline levels on warfarin (Fig. 1B-3B); median 
[CI] for C3a, C5a and SC5b-9 for rivaroxaban (day 42) versus warfarin (day 0): C3a (ng/mL) 64 
(29-125) vs 83 (35-147), (p=0.004); C5a (ng/mL) 9 (2 - 15) vs 12.0 (4 -18), p=0.02; and SC5b-9 
(ng/mL) 171 (56-245) vs 201 (66-350), (p=0.002). However, there were no significant 
differences in median levels of Bb fragment, between baseline and day 42 on rivaroxaban 
(Fig. 4B). Of the 55 patients randomised to receive rivaroxaban, 22 (40%), 25 (45%), 38 
(69%) and 19 (35%) had elevated C3a, C5a, SC5b-9 and Bb, respectively at baseline. Of 
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these, all patients showed a decrease in C3a (mean decrease 24%) and C5a (mean decrease 
32%), 35/38 in SC5b-9 (mean decrease 25%) and 14/19 in Bb (mean decrease 11%), at day 
42 after switching to rivaroxaban (Fig. 5). Compared to the group remaining on warfarin, the 
decreases in values associated with rivaroxaban were significant for C3a (p<0.009, OR 54.5, 
CI 2.9-1022.0), C5a (p<0.005, OR 24.6, CI 1.3-470.0), and SC5b-9 (p<0.005, OR 9.6, CI 2.6-
36.3).  
There were no significant correlations between rivaroxaban levels and C3a, C5a, SC5b-9, or 
Bb fragment levels and there were no significant associations between higher or lower 
rivaroxaban concentrations (top and bottom tertiles 190-461 and 50-138ng/ml, 
respectively) and elevated complement markers.   
Discussion 
This study demonstrates, in the context of the RAPS RCT, that APS patients with previous 
VTE treated with warfarin exhibit significantly increased complement activation compared 
with NC, in agreement with previous studies [14;16]. The mechanism of this and which 
pathway is involved is unclear (activation could occur through the classical, lectin, or 
alternative pathways), since C3a, C5a, SC5b-9 and Bb fragment were all elevated. The novel 
observation in this study is that this complement activationis significantly decreased by 
administration of rivaroxaban, a direct FXa inhibitor. Our data indicate that the limiting 
effect of rivaroxaban on complement activation is likely to occur via the classical pathway as 
patients treated with rivaroxaban had significantly lower anaphylatoxins (C3a and C5a) and 
terminal complement component (SC5b-9), with Bb fragment (a marker of alternative 
pathway activation) unchanged. We did not measure specific markers of the lectin pathway; 
however, preliminary evidence from Breen et al suggests a lack of association of the lectin 
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pathway and complement activation in patients with aPL [34]. There were no correlations 
between rivaroxaban levels and C3a, C5a, SC5b-9 and Bb fragment levels.  
In this study, increased C3a, C5a, SC5b-9 and Bb fragment levels were not associated with 
the presence of triple positivity for aPL or LA and no significant differences in complement 
activation marker levels were observed between patients with primary APS and those with 
SLE-associated APS. Other studies have also reported significantly increased levels of 
complement activation markers in APS patients compared to NC [14;16] in APS patients.  In 
a study of 186 patients with aPL (95 with previous thrombotic complications, 52 with 
obstetric APS and 39 with asymptomatic aPL), Breen et al [16] found significantly increased 
levels of fragment Bb and C3a compared to NC. Oku et al [14], studied 36 primary APS 
patients, 42 non-SLE connective tissue diseases, and 36 NC, and found that primary APS 
patients with low serum C3 or C4 had significantly higher levels of C3a or C4a than the 
control groups. Among patients with primary APS, hypocomplementemia was significantly 
more frequent in patients with LA, although no relationship was found with the clinical 
manifestations of APS. Devreese et al [35] also found increased levels of C3a in patients with 
aPL, but used citrate rather than EDTA plasma samples, which may result in higher levels of 
C3a and other markers due to in vitro complement activation. Overall, the clinical studies, 
including our observations and animal data support the hypothesis that complement 
activation may play a major role in the pathogenesis of APS [14-26].  
The mechanism of rivaroxaban-induced inhibition of complement activation is unknown but 
may be related to its FXa inhibitory effect; either by direct inhibition of FXa proteolysis and 
activation of complement proteins, or indirectly by inhibition of pro-inflammatory effects of 
FXa with downstream complement activation. FXa mediated activation of the complement 
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system in vitro is characterised by physiological (2μg/mL) and supraphysiological FXa levels 
(20-1002μg/mL), whereas thrombin induced cleavage is observed mainly at 
supraphysiological thrombin levels [2]. However, these observations were made in the 
absence of a phospholipid surface and may not apply in vivo. FXa also activates protease 
activated receptor-1 (PAR-1) and PAR-2 receptors on the vascular endothelium, leading to 
upregulation of intracellular processes and inflammatory reactions [36-38]. Heparin which 
inhibits FXa and thrombin, has inhibitory effects on the production of proinflammatory 
cytokines from LPS-stimulated monocytes [39] and an anti-inflammatory effect during 
venous thrombosis [40], which could contribute to its inhibitory action on complement 
activation [41;42]. In a mouse model of sickle cell disease, dabigatran, a direct thrombin 
inhibitor, and rivaroxaban have been demonstrated to reduce both systemic and local 
inflammatory responses through inhibition of thrombin and FXa respectively [43]. However, 
translation of the results from mouse models to humans is limited because of differences in 
the coagulation and complement systems and also their regulation [44]. 
The differences in C3a, C5a and SC5b-9 levels, but not Bb fragment, between APS patients 
treated with rivaroxaban or warfarin could be due to variation in the degree of activation of 
the AP and CP. Although patients treated with rivaroxaban had significantly lower 
complement activation markers compared to patients treated with warfarin, both patient 
groups had complement activation marker levels significantly above those of the NC.  
The lack of correlation observed between complement activation markers and rivaroxaban 
levels, or INR (in warfarin-treated patients), suggests that the effects on complement 
activation were not related to the intensity of anticoagulation.  
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In this study, complement activation was tested when peak rivaroxaban concentrations  
were expected, with  maximal inhibition of factor Xa, however some patients had 
rivaroxaban levels lower than expected (<160 ng/mL) at 2-4 hours after the last rivaroxaban 
dose (based on population pharmacokinetics studies) [45]. Patients with lower rivaroxaban 
levels did not have significant differences in C3a, C5a and SC5b-9 levels compared to those 
with  expected therapeutic (or higher) rivaroxaban levels, suggesting that patients treated 
with rivaroxaban have stable inhibition of complement activation. Furthermore, 
complement activation markers have short half lives (C5a ~1min, C3a a few hours, SC5b-9 
50-60min) [12;46;47] therefore, complement activation is likely to involve a chronic, 
continuous mechanism. Since warfarin affects the post-translational maturation of FX, 
reducing plasma FX levels and decreasing its ability to bind phospholipid surfaces, it may not 
be able to abolish complement activation, whereas rivaroxaban being a small, high affinity, 
direct FXa inhibitor is able to be more effective. 
Rivaroxaban, as well as being efficacious, safe and convenient, is fixed dose with predictable 
effect (so that routine anticoagulant monitoring is not required), and has fewer drug 
interactions than warfarin. Results of the RAPS trial (completed) and other clinical studies 
(ongoing) [48-50] will provide more robust information on the role of rivaroxaban and other 
DOACs in patients with thrombotic APS, and put into context anecdotal case reports and 
small case series of recurrent thrombosis after switching APS patients from warfarin to a 
DOAC [51-54]. Rivaroxaban significantly reduced complement activation compared to 
warfarin, with an absolute mean reduction in C5a of 32% and in SC5b-9 of 25%. Although 
complement activation was not restored to normal levels, it is biologically plausible that an 
inhibitory effect of rivaroxaban on complement activation may potentially provide benefit 
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additional or adjunctive to its anticoagulant effect in patients with APS. Such an effect of  
rivaroxaban in preventing complement activation might also have wider applicability in 
other thrombotic states associated with complement activation, such as PNH, where VTE is 
the main cause of mortality, accounting for 40–67% of PNH-related deaths [11]. When such 
patients require long-term anticoagulation, the use of rivaroxaban may be valuable in 
restricting overall complement activation in addition to its anticoagulant effect. The 
limitations of this study are that: complement activation markers were only assessed at a 
single time point in each patient and the degree of activation may vary with time; and we 
did not use assays that discriminate between classical and lectin pathway activation. Future, 
in vitro studies are required to confirm the route of complement activation in APS, the role 
of FXa and the mechanism of reduction of complement activation by FXa inhibitors.  
In conclusion, we describe the novel observation that rivaroxaban limits complement 
activation in APS patients with previous VTE compared with warfarin. This action of 
rivaroxaban is likely to occur via the classical pathway as patients treated with rivaroxaban 
had significantly lower anaphylatoxins (C3a and C5a) and terminal complement component 
(SC5b-9), but Bb fragment (a marker of alternative pathway activation) was unchanged. The 
observations in rivaroxaban-treated patients may reflect inhibition of factor Xa cleavage of 
complement proteins, or inhibition of its pro-inflammatory effects (and consequent 
complement activation). Rivaroxaban may therefore potentially provide benefit additional 
to its anticoagulant effect in this patient group by limiting complement activation.  
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Table 1. Baseline characteristics and aPL status of study participants   
Characteristics Normal controls 
(N=55) 
   Rivaroxaban 
    (N=55) 
  Warfarin 
  (N=56) 
Age (years) mean (SD) 41 (12)       47 (17)    50 (14) 
 
Sex            Male 
 N (%)        Female 
 
19 (35) 
39 (65) 
      15 (26) 
      42 (72) 
   17 (29) 
   42 (71) 
Number of SLE patients (%) n/a      11 (19) 
 
   11 (19) 
CrCL (mL/min) 
Mean (CI) 
Not done       92.1 (85.2 to 99.6)    95.4 (87.8 to 103.7) 
    
ALT (IU/L) Not done       21.2 (18.6 to 24.1)     19.6 (17.4 to 22.2) 
 
Median INR (CI)   Baseline 
                               Day 42 
 
n/a 
n/a 
      2.6 (2.3-2.9) 
      n/a 
    2.7 (2.4-3.0) 
    2.6 (2.3-2.8) 
Rivaroxaban  level (ng/mL) 
Median (CI)  
n/a      155 (139-184) 
  
    n/a 
 
APS- defining aPL (Miyakis 
categories): 
Category I   
Category II :IIa, 
                     IIb 
                    IIC  
 
 
 
n/a 
 
 
 
    23/55 
    29/55 
      2/55 
      1/55 
 
 
 
  32/56 
  21/56 
    3/56 
    0/56 
SD = standard deviation; CI = confidence interval; SLE = systemic lupus erythematosus; INR = 
international normalized ratio; n/a = not applicable; aPL = antiphospholipid antibodies. 
The Miyakis (29) antiphospholipid syndrome categories were as follows:  I:  the presence of 
more than one aPL in any combination;  IIa: presence of lupus anticoagulant alone; IIb: 
anticardiolipin antibody present alone; IIc: anti-β2 glycoprotein-I antibody present alone. 
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Figure 1 
Comparison of C3a levels in patients randomised to remain on warfarin (A) or to switch to 
rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.  
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Figure 2 
Comparison of C5a levels in patients randomised to remain on warfarin (A) or to switch to 
rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.  
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Figure 3 
Comparison of SC5b-9 levels in patients randomised to remain on warfarin (A) or to switch 
to rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.  
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Figure 4 
Comparison of Bb fragment levels in patients randomised to remain on warfarin (A) or to 
switch to rivaroxaban (B), at day 42 compared to their baseline values and with normal 
controls.  
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Figure 5 
Patients with baseline elevation of C5a (A) or SC5b-9 (B) –effect of rivaroxaban 
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